Read by QxMD icon Read

Pemphigoid dpp

Aikaterini Patsatsi, Aikaterini Kyriakou, Parthena Meltzanidou, Anastasia Trigoni, Foteini Lamprou, Miltiadis Kokolios, Anastasia Giannakou
No abstract text is available yet for this article.
October 15, 2018: European Journal of Dermatology: EJD
Khalaf Kridin, Reuven Bergman
Importance: The association of bullous pemphigoid (BP) with the use of dipeptidyl-peptidase 4 (DPP-4) inhibitors among patients with diabetes has recently emerged. The risk of developing BP during treatment with new DPP-4 inhibitor agents like linagliptin is yet to be established. The clinical features and the prognostic outcomes of patients with DPP-4 inhibitor-associated BP are yet to be established. Objectives: Primarily to estimate the association between DPP-4 inhibitor exposure and the development of BP, and secondarily to characterize the clinical features and history of patients with DPP-4 inhibitor-associated BP...
October 1, 2018: JAMA Dermatology
Outi Varpuluoma, Anna-Kaisa Försti, Jari Jokelainen, Miia Turpeinen, Markku Timonen, Kaisa Tasanen, Laura Huilaja
BACKGROUND: Dipeptidyl peptidase 4 inhibitors (DPP4is) used to treat diabetes have been reported to be associated with an increased risk of bullous pemphigoid (BP). There are no previous reports analyzing the risk of BP in patients who are using other diabetes medications. OBJECTIVE: To evaluate the association between diabetes medications other than DPP4i and development of BP. METHODS: We investigated the prevalence of diabetes among patients with BP and the association between the use of diabetes drugs (excluding DPP4i, metformin, and insulin) and BP by analyzing national Finnish registry data for 3397 patients with BP and 12,941 patients with basal cell carcinoma as controls...
December 2018: Journal of the American Academy of Dermatology
Irene García-Díez, Marta Ivars-Lleó, Daniel López-Aventín, Norito Ishii, Takashi Hashimoto, Pilar Iranzo, Ramon M Pujol, Agustín España, Josep E Herrero-Gonzalez
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors have increasingly been identified as causative agents of bullous pemphigoid. The clinical and immunological characteristics of this pemphigoid variant are still unclear. The objective of our study was to analyze the clinical and immunological features of patients with pemphigoid induced by DPP-4 inhibitors. METHODS: All patients diagnosed with DPP-4 inhibitor-associated bullous pemphigoid at dermatology departments in three Spanish centers during the period 2013 to 2015 were included...
July 2018: International Journal of Dermatology
L Fania, G Di Zenzo, C Mazzanti, D Abeni
No abstract text is available yet for this article.
March 23, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
A Gravani, G Gaitanis, T Tsironi, S Tigas, I D Bassukas
No abstract text is available yet for this article.
March 23, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
Chika Chijiwa, Shintaro Takeoka, Masahiro Kamata, Mihoko Tateishi, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Shinichi Watanabe, Yayoi Tada
Bullous pemphigoid (BP) is an acquired autoimmune blistering disease in which autoantibodies against epitopes in the basement membrane zone of the skin such as BP180 or BP230 are produced. Dipeptidyl peptidase (DPP)-4 inhibitors have become commonly used to treat diabetes. As DPP-4 inhibitors are more commonly prescribed for diabetes, BP related to DPP-4 inhibitors has been reported and has attracted attention. Therefore, we retrospectively investigated patients who were diagnosed with BP in order to examine characteristics of DPP-4 inhibitor-related BP (nine patients; median age, 85 years) in comparison with non-DPP-4 inhibitor-related BP (21; median age, 85 years)...
May 2018: Journal of Dermatology
Hideyuki Ujiie, Ken Muramatsu, Taisei Mushiroda, Takeshi Ozeki, Hideaki Miyoshi, Hiroaki Iwata, Akinobu Nakamura, Hiroshi Nomoto, Kyu Yong Cho, Norihiro Sato, Machiko Nishimura, Takamasa Ito, Kentaro Izumi, Wataru Nishie, Hiroshi Shimizu
No abstract text is available yet for this article.
May 2018: Journal of Investigative Dermatology
L Fania, G Di Zenzo, B Didona, M A Pilla, L Sobrino, A Panebianco, C Mazzanti, D Abeni
No abstract text is available yet for this article.
April 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
Masaru Harada, Akitoshi Yoneda, Sanehito Haruyama, Kei Yabuki, Yuichi Honma, Masaaki Hiura, Michihiko Shibata, Hidehiko Matsuoka, Yasuhiro Uchiwa
A 78-year-old man presented with cutaneous blisters of the limbs and abdominal distension. He had been treated for various diseases, including liver cirrhosis. He had begun receiving sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, for diabetes mellitus three years before the hospitalization. A skin biopsy demonstrated bullous pemphigoid. Ultrasonography (US) revealed multiple liver tumors, although he had been receiving regular US studies. We stopped sitagliptin and started insulin and corticosteroids...
September 15, 2017: Internal Medicine
Satoshi Yoshiji, Takaaki Murakami, Shin-Ichi Harashima, Rie Ko, Riko Kashima, Daisuke Yabe, Masahito Ogura, Kentaro Doi, Nobuya Inagaki
Bullous pemphigoid (BP) is an autoimmune blistering skin disorder. Recently, BP induced by dipeptidyl peptidase-4 (DPP-4) inhibitors has been a concern. Although DPP-4 inhibitors are commonly used in the Asian population because of their safety and efficacy, BP associated with DPP-4 inhibitors is sometimes seen in clinical settings. Here, we report five Japanese cases of BP associated with the agents. In the present cases, BP occurred in older adults using four different DPP-4 inhibitors, which showed various clinical manifestations in terms of latency period for BP, sex, glycemic control and diabetes duration...
March 2018: Journal of Diabetes Investigation
J Béné, G Moulis, I Bennani, M Auffret, P Coupe, S Babai, D Hillaire-Buys, J Micallef, S Gautier
BACKGROUND: Inhibitors of dipeptidyl peptidase (DPP)-IV have been suspected in the onset of bullous pemphigoid for several years now. However, comparative studies assessing the link between DPP-IV inhibitor exposure and bullous pemphigoid have not yet been performed. OBJECTIVES: To detect, from the French Pharmacovigilance Database (FPVD), a signal of risk of bullous pemphigoid during DPP-IV inhibitor exposure by comparative study. METHODS: All spontaneous reports of DPP-IV inhibitor-related bullous pemphigoid recorded in the FPVD between April 2008 and August 2014 were described...
August 2016: British Journal of Dermatology
Francisco Manuel Ildefonso Mendonça, Francisco José Martín-Gutierrez, Juan José Ríos-Martín, Francisco Camacho-Martinez
BACKGROUND: Bullous pemphigoid (BP) is an acquired subepidermal autoimmune blistering disease in which there are humoral and cellular responses against the BP180 and BP230 antigens. Dipeptidyl peptidase (DPP)-4 inhibitors enhance endogenous glucagon peptide-1 and glucose-dependent insulinotropic polypeptide secretion with food intake, which leads to insulin secretion, as well as to the reduction of glucagon secretion. Recently, several cases of DPP-4 inhibitor-associated BP have been reported...
2016: Dermatology: International Journal for Clinical and Investigative Dermatology
Amy Attaway, Tracey L Mersfelder, Sakshi Vaishnav, Joanne K Baker
BACKGROUND: Bullous pemphigoid is a cutaneous autoimmune blistering disorder. The etiology for what precipitates this disease is not entirely clear at this point, although it has been associated with certain medications. MAIN OBSERVATION: We describe the case of a 70-year-old male with a past medical history of diabetes type 2 who developed a diffuse eruption of bullae with skin biopsy positive for bullous pemphigoid. He had previously been prescribed sitagliptin 50 mg daily for at least one year prior to onset of his disease...
March 31, 2014: Journal of Dermatological Case Reports
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"